Blood Plasma Fractionation Market to Grow at CAGR of 8.51% through 2030
Increasing
number of plasma collection centers and the supportive regulatory frameworks is
expected to drive the Global Blood Plasma Fractionation Market growth in the
forecast period, 2026-2030.
According to
TechSci Research report, “Blood Plasma Fractionation Market – Global Industry
Size, Share, Trends, Competition, Forecast & Opportunities, 2020-2030F”,
the Global Blood Plasma Fractionation Market stood at USD 35.76 Billion in 2024 and is
expected to reach USD 58.51 Million by 2030 with a CAGR of 8.51% during the
forecast period.
The Global Blood
Plasma Fractionation Market is experiencing significant growth, driven by
several factors such as increasing demand for plasma-derived therapies, rising
prevalence of chronic and rare diseases, advancements in healthcare
infrastructure, and ongoing research into new therapeutic applications. As a
critical component of the biopharmaceutical industry, blood plasma
fractionation involves the separation of plasma into its individual proteins
for use in medical treatments, most notably for diseases like hemophilia,
immune deficiencies, and autoimmune disorders. Over the past decade, the market
has seen substantial developments in both demand and technology, shaping a
dynamic and expanding landscape.
One of the key
drivers of growth in the market is the rising global incidence of diseases that
require plasma-derived therapies. Chronic conditions such as rheumatoid
arthritis, multiple sclerosis, and primary immunodeficiencies have become more
prevalent, especially in developed nations. The aging global population is more
susceptible to conditions like infections and autoimmune disorders, further
increasing the need for immunoglobulins and other plasma products.
Plasma-derived therapies are integral in treating diseases like hemophilia,
where coagulation factors are necessary to prevent excessive bleeding, and in
autoimmune diseases where intravenous immunoglobulins (IVIG) are used to
regulate the immune system.
The demand for
immunoglobulins, particularly IVIG, is one of the main forces driving the
market. IVIG is used in a wide range of applications, from primary
immunodeficiencies to autoimmune disorders, and its growing use in treatments
for conditions like Guillain-Barré syndrome and chronic inflammatory
demyelinating polyneuropathy (CIDP) has fueled its prominence. As more medical
conditions are being explored for potential treatments with immunoglobulins,
the overall demand for plasma-derived therapies is surging. Albumin, another
plasma protein used to treat liver diseases, burns, and shock, also remains in
high demand, further contributing to the market's growth.
A significant
contributing factor to the expansion of the global blood plasma fractionation
market is the increasing focus on plasma collection. Countries with
well-established plasma collection centers, such as the United States, are
continuously expanding their networks to meet growing demand. The United
States, in particular, has a highly efficient plasma collection system,
supported by compensation for donors, which incentivizes more frequent
donations. Plasma donation is also encouraged in many other regions, including
Europe and parts of Asia, as the importance of plasma in medical treatments
becomes more recognized. However, challenges related to plasma shortages
persist in certain regions, especially in areas where donation rates are lower
or where the healthcare infrastructure is less developed. This shortage has led
to increased competition among plasma fractionators to secure a stable and
sufficient supply of raw plasma for fractionation.
Technological
advancements in plasma fractionation technologies are also playing a crucial
role in driving market growth. Innovations in the methods used to separate
plasma into its individual proteins have resulted in higher yield and
efficiency in the production of plasma-derived therapies. Fractionation
processes have become more cost-effective, allowing for greater production
capacity and the potential to meet the increasing demand for these life-saving
products. Continuous improvements in quality control and safety measures have
minimized the risks associated with plasma-derived products, such as the
transmission of infections, and enhanced the overall safety profile of these
therapies. The development of more refined, scalable technologies is expected
to support the market’s expansion in the coming years.
In addition to
technological advances, the market is also benefitting from regulatory support
and an increasing focus on personalized medicine. Regulatory agencies such as
the U.S. Food and Drug Administration (FDA) and the European Medicines Agency
(EMA) ensure the safety and efficacy of plasma-derived products through
stringent regulations, creating a reliable and secure framework for both
producers and patients. The shift toward personalized and targeted therapies is
opening new opportunities for plasma-derived products. Gene therapies and other
cutting-edge medical treatments are being explored in conjunction with plasma
therapies, potentially increasing the scope of plasma-derived products in
treating a broader array of conditions.
However, the
market faces challenges, including high production costs associated with plasma
collection, processing, and fractionation. The high cost of plasma-derived
products can make them less accessible, particularly in developing countries. Ethical
concerns surrounding the commercialization of plasma donations and the
potential for exploitation in low-income regions present challenges for the
industry. Despite these challenges, the increasing demand for plasma-derived
therapies and the potential for continued technological advancements provide a
promising outlook for the market.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Blood Plasma Fractionation Market”
The Global Blood
Plasma Fractionation Market is segmented into product, method, application, end
use, regional distribution, and company.
Based on method,
the chromatography was the dominant technique in the global market.
Chromatography plays a critical role in the separation, purification, and
analysis of plasma proteins, which are essential for producing life-saving
plasma-derived therapies such as immunoglobulins, albumin, and coagulation
factors. The ability to precisely isolate specific proteins from blood plasma
is crucial for ensuring the quality, safety, and efficacy of these
therapeutics, making chromatography the leading method in plasma fractionation
processes.
Chromatography
techniques, such as affinity chromatography, ion-exchange chromatography, and
size-exclusion chromatography, allow for the targeted separation of proteins
based on their physical and chemical properties. For example, affinity
chromatography is widely used for isolating specific proteins like
immunoglobulins, where the process is designed to specifically capture
antibodies based on their affinity for certain ligands. This targeted
separation ensures that the plasma-derived products meet the required
therapeutic standards in terms of purity and concentration. Ion-exchange
chromatography, on the other hand, is particularly effective for separating
plasma proteins based on their charge, while size-exclusion chromatography
separates proteins by size, which is critical for isolating specific fractions
like albumin and clotting factors.
The reason
chromatography dominates the global blood plasma fractionation market is due to
its high precision, scalability, and ability to produce highly purified
products, which are essential for therapeutic use. As the demand for
high-quality plasma-derived therapies increases, the need for robust and
efficient purification methods becomes even more critical. Chromatography
provides an ideal solution to this need by offering the ability to isolate
proteins with high specificity and minimal contamination, ensuring that the
final product is safe for patient use.
Based on region,
Europe stands as the second dominant region in the global blood plasma
fractionation market. Europe’s strong presence in the plasma fractionation
industry is attributed to its well-established healthcare infrastructure,
robust regulatory environment, and high demand for plasma-derived therapies.
The region is home to several key players in the blood plasma fractionation
market, both in terms of manufacturers and research and development
initiatives.
One of the major
factors driving the dominance of Europe in the blood plasma fractionation
market is the increasing prevalence of chronic and rare diseases, such as
autoimmune disorders, hemophilia, and primary immunodeficiencies, which require
plasma-derived therapies. As the population ages, the need for immunoglobulins,
albumin, and coagulation factors has risen significantly. With Europe’s aging
population and high rates of chronic diseases, healthcare systems across the
region are increasingly reliant on plasma-based treatments to manage these
conditions. For instance, immunoglobulins (IVIG) are widely used in Europe for
treating immune disorders, while albumin is crucial in managing shock, burns,
and liver diseases. The high demand for these therapies drives the blood plasma
fractionation market’s growth in Europe.
Europe has an
advanced healthcare system with cutting-edge medical facilities and highly
skilled professionals, which enables the proper administration of
plasma-derived therapies. Hospitals and clinics in Europe are equipped with the
necessary infrastructure to deliver plasma-based treatments effectively,
contributing to a large volume of consumption of these products. As awareness
of the effectiveness of plasma-derived therapies increases, more patients are
being diagnosed with conditions that require these treatments, further
bolstering the market.
Major companies
operating in Global Blood Plasma Fractionation Market are:
- Grifols, S.A.
- CSL Limited
- Takeda Pharmaceutical Company
Limited
- Octapharma AG
- Kedrion S.p.A
- Biotest AG
- Bio Products Laboratory Ltd.
- Intas Pharmaceuticals Ltd.
- ADMA Biologics, Inc.
- Meiji Holdings Co., Ltd.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The future of
the global blood plasma fractionation market looks promising, driven by the
increasing demand for plasma-derived therapies, advancements in fractionation
technologies, and a rising prevalence of chronic and rare diseases. The market
is expected to grow significantly as new applications for plasma products
emerge, particularly in immunotherapy, autoimmune diseases, and genetic
disorders. The expansion of plasma collection networks, especially in emerging
markets, will ensure a steady supply of raw plasma. Ongoing research and
regulatory advancements will enhance the safety and efficacy of plasma
therapies. With a focus on personalized medicine and innovative treatments, the
market is set to see continued growth, offering opportunities for market
leaders to expand their presence globally while addressing the rising
healthcare needs.,” said Mr. Karan Chechi, Research Director of TechSci Research,
a research-based management consulting firm.
“Blood Plasma Fractionation Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Albumin,
Immunoglobulins, Coagulation Factors, Protease Inhibitors and Others), By
Method (Centrifugation, Depth Filtration, Chromatography, and Others), By
Application (Neurology, Haematology, Oncology, Immunology, Pulmonology, and
Others), By End Use (Hospitals & Clinics, Clinical Research, and Others), By
Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Blood Plasma Fractionation Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Blood Plasma Fractionation Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com